Ultrasound (US) Guided External Ventricular Catheter Placement
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sara Craig, MNR, BS
- Phone Number: 285799 717-531-0003
- Email: scraig2@pennstatehealth.psu.edu
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Recruiting
- Penn State Health Milton S. Hershey Medical Center
-
Contact:
- Sara Craig Clinical Research Coordinator, BS, MNR
- Phone Number: 285799 717-531-0003
- Email: Scraig2@pennstatehealth.psu.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Decision made to perform the procedure by the primary consultant
- Age 18 or older
- Neuro ICU stay
- Newly diagnosed hydrocephalus
- Has a recent CT within the past 24 hrs
- Normal platelets and coagulation profile
- No active infection or currently on antibiotics
- The targeted fluid compartment has more than 50 percent CSF vs blood by CT scan imaging
Exclusion Criteria:
- Age <18
- Not in Neuro ICU setting
- Previous placement of a ventricular catheter
- More than 50 percent of the fluid compartment is filled with blood by CT scan
- Time to include in the trial prohibited by clinical personnel
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Catheter placement with Solopass system
The Solopass US system will be used during catheter placement procedure to guide the placement of the catheter.
|
This device is used as a guidance for placing a brain catheter to target the brain ventricles and decrease multiple brain passes, incorrect deployment and malfunctioning of the drain.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average number of passes needed to place the catheter in each subject.
Time Frame: 0 minutes
|
Measured by the number of passes needed to place the catheter.
If the first attempt fails, another US sweep will be performed, and another attempt will be performed.
If that fails, then the procedure will be aborted.
|
0 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post procedure imaging accuracy of the placement of the EVD will be performed by reviewing post procedure imaging using the Kakarla scoring system
Time Frame: up to 7 days
|
Grade 1 means optimal placement in the ipsilateral frontal horn or third ventricle; Grade 2 means a functional placement in the contralateral lateral ventricle or no eloquent cortex; and Grade 3 means suboptimal placement in the eloquent cortex or nontarget cerebrospinal fluid space, with or without functional drainage
|
up to 7 days
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of time of the procedure
Time Frame: Up to three hours
|
Number of minutes necessary to complete the procedure placement of the catheter
|
Up to three hours
|
|
Number of revision
Time Frame: up to 7 days
|
Quantity of revisions due to the catheter malfunction
|
up to 7 days
|
|
Number of subjects with Cerebrospinal fluid (CSF) infection
Time Frame: up to 7 days
|
CSF will be collected as part of standard of care after the procedure and tested for infection.
|
up to 7 days
|
|
Number of subjects with Superficial surgical site infection (SSI)
Time Frame: up to 7 days
|
(The CDC defines SSI as deep and superficial.
A superficial incisional SSI is an infection in the area of the skin where the incision was made.
A deep incisional SSI occurs beneath the incision area in the muscle and the tissues surrounding the muscles.
Signs to be monitored daily and put in a checklist will include redness, pain, unexplained fever source, pain, warmth, pus or swelling.)
|
up to 7 days
|
|
Longevity of the device function
Time Frame: up to 7 days
|
Number of days until a subsequent catheter is placed
|
up to 7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: J C Zacko, MD, Milton S. Hershey Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY00022095
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.